Pascolizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIL-4
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002.[2] Development was discontinued as it showed little benefit.[3]

References

  1. ^ Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (October 2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
  2. ^ Clinical trial number NCT00024544 for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" at ClinicalTrials.gov
  3. ^ Bice JB, Leechawengwongs E, Montanaro A (2014). "Biologic targeted therapy in allergic asthma". Annals of Allergy, Asthma & Immunology. 112 (2): 108 - 115. doi:10.1016/j.anai.2013.12.013.
Categories